S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
NASDAQ:CRBU

Caribou Biosciences (CRBU) Stock Price, News & Analysis

$3.85
-0.06 (-1.53%)
(As of 04/19/2024 ET)
Today's Range
$3.78
$4.03
50-Day Range
$3.85
$8.26
52-Week Range
$3.44
$8.59
Volume
1.71 million shs
Average Volume
1.56 million shs
Market Capitalization
$347.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.50

Caribou Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
484.4% Upside
$22.50 Price Target
Short Interest
Bearish
12.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Caribou Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.76) to ($2.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.49 out of 5 stars

Medical Sector

688th out of 909 stocks

Biological Products, Except Diagnostic Industry

115th out of 149 stocks

CRBU stock logo

About Caribou Biosciences Stock (NASDAQ:CRBU)

Caribou Biosciences, Inc. is a cutting-edge biopharmaceutical company headquartered in Berkeley, California. Founded in 2011 by Dr. Rachel E. Haurwitz and other prominent scientists, the company is a leader in the field of genome-editing therapies. Caribou utilizes CRISPR-Cas technology to develop precision cell therapies for patients suffering from hematologic malignancies and solid tumors. The company's vision is to revolutionize the treatment landscape for devastating diseases by providing innovative and personalized therapies.

Caribou Biosciences' journey began as a spinoff from research conducted at the University of California, Berkeley, where Dr. Haurwitz and her colleagues worked on harnessing the CRISPR-Cas system for advanced gene-editing applications. Leveraging their expertise, the team established Caribou to explore the potential of genome editing in developing transformative therapeutics.

The company is committed to pushing the boundaries of science and medicine, focusing on creating precision cell therapies that target specific genetic mutations in patients' cells. By modifying these cells, Caribou aims to enhance antitumor activity and provide tailored treatments to address the unique genetic characteristics of each patient's disease.

Caribou Biosciences operates in the biological products industry, specializing in genome-editing therapies. The company's dedication to research and innovation has positioned it as a key player in the field, with significant potential to impact the future of medical treatments.

The company's mission statement revolves around the core belief in the power of genome-editing technology to unlock new possibilities for disease treatment and patient care. Caribou is committed to advancing its pipeline of precision cell therapies and translating cutting-edge science into transformative solutions for patients worldwide.

The leadership team at Caribou Biosciences comprises accomplished professionals with extensive expertise in the biopharmaceutical and scientific domains. Dr. Rachel E. Haurwitz, who co-founded the company and serves as the Chief Executive Officer, President, and Director. With a Ph.D. in Molecular and Cell Biology from UC Berkeley, Dr. Haurwitz was pivotal in developing CRISPR-based gene-editing technologies. Assisting Dr. Haurwitz is Ms. Ruhi A. Khan, the Chief Business Officer responsible for driving strategic partnerships and business development initiatives. Ms. Khan brings a wealth of experience in the biopharmaceutical industry and has been instrumental in shaping Caribou's collaborations. Dr. Syed Ali-aamir Rizvi serves as the Chief Medical Officer, contributing his expertise in clinical development and medical affairs. With a strong background in hematology and oncology, Dr. Rizvi is critical in guiding the clinical progress of Caribou's precision cell therapies. The management team's collective experience, dedication to innovation, and scientific prowess have propelled Caribou Biosciences to the forefront of the genome-editing industry.

Caribou Biosciences has demonstrated steady revenue growth over the past few years. However, the company is operating at a loss, with a net negative income of close to $100 million. The negative net profit margins result from substantial operating expenses associated with advancing the pipeline of precision cell therapies. Caribou Biosciences' innovative approach to precision cell therapies and its pioneering work in genome editing have garnered investor interest and positive sentiment, contributing to the stock's potential upside.

The stock performance of Caribou Biosciences is subject to various factors, including market conditions, investor sentiment, and news related to the company's progress. Investors closely monitor the company's milestones, clinical trial results, and partnership agreements, which can significantly impact the stock price.

Caribou Biosciences operates in the highly competitive field of biopharmaceuticals, focusing on genome-editing therapies. The broader industry has witnessed significant advancements in CRISPR technology, with various companies vying to develop precision cell therapies. Caribou's competitive advantage lies in its patented Cas12a chRDNA technology, which enables superior precision in genome editing and the development of armored cell therapies.

The company's pipeline of precision cell therapies presents promising growth opportunities. With its CAR-T and CAR-NK platforms targeting hematologic malignancies and solid tumors, Caribou aims to cater to patients with critical medical needs. The company's dedication to scientific excellence and pioneering research positions it well to capitalize on the potential of genome-editing therapies.

Caribou Biosciences faces several potential risks and challenges common to clinical-stage biopharmaceutical companies. These include uncertainties in clinical trials, regulatory approval processes, and market competition. However, Caribou's risk management strategies and scientific expertise serve as potential mitigating factors.

CRBU Stock Price History

CRBU Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
CRBU Oct 2024 5.000 put
Caribou Biosciences Shares Fall on Wall Street Miss
CRBU Oct 2024 2.500 call
CRBU Mar 2024 7.500 put
See More Headlines
Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CRBU
Fax
N/A
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.50
High Stock Price Target
$30.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+484.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-102,070,000.00
Net Margins
-296.05%
Pretax Margin
-295.49%

Debt

Sales & Book Value

Annual Sales
$34.48 million
Book Value
$4.17 per share

Miscellaneous

Free Float
81,735,000
Market Cap
$347.73 million
Optionable
Optionable
Beta
2.47
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives


CRBU Stock Analysis - Frequently Asked Questions

Should I buy or sell Caribou Biosciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Caribou Biosciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRBU shares.
View CRBU analyst ratings
or view top-rated stocks.

What is Caribou Biosciences' stock price target for 2024?

4 brokers have issued 12-month price targets for Caribou Biosciences' stock. Their CRBU share price targets range from $13.00 to $30.00. On average, they expect the company's share price to reach $22.50 in the next year. This suggests a possible upside of 484.4% from the stock's current price.
View analysts price targets for CRBU
or view top-rated stocks among Wall Street analysts.

How have CRBU shares performed in 2024?

Caribou Biosciences' stock was trading at $5.73 at the beginning of 2024. Since then, CRBU stock has decreased by 32.8% and is now trading at $3.85.
View the best growth stocks for 2024 here
.

When is Caribou Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CRBU earnings forecast
.

How were Caribou Biosciences' earnings last quarter?

Caribou Biosciences, Inc. (NASDAQ:CRBU) issued its earnings results on Monday, March, 11th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.17. The firm earned $3.56 million during the quarter, compared to analysts' expectations of $5.17 million. Caribou Biosciences had a negative trailing twelve-month return on equity of 31.06% and a negative net margin of 296.05%.

What ETFs hold Caribou Biosciences' stock?
When did Caribou Biosciences IPO?

Caribou Biosciences (CRBU) raised $202 million in an IPO on Friday, July 23rd 2021. The company issued 13,500,000 shares at a price of $14.00-$16.00 per share.

Who are Caribou Biosciences' major shareholders?

Caribou Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Green Alpha Advisors LLC (0.09%) and Allspring Global Investments Holdings LLC (0.05%). Insiders that own company stock include Barbara G Mcclung, Ryan Fischesser, Steven Kanner and Syed Ali-Aamir Rizvi.
View institutional ownership trends
.

How do I buy shares of Caribou Biosciences?

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRBU) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners